Multilayered Modelling of the Metallation of Biological Targets

[1]  K. Baumann,et al.  A gold(i) biscarbene complex with improved activity as a TrxR inhibitor and cytotoxic drug: comparative studies with different gold metallodrugs. , 2019, Metallomics.

[2]  T. Benedek.  The History of Gold Therapy for Tuberculosis , 2004, Journal of the history of medicine and allied sciences.

[3]  S. Lippard,et al.  Testis-specific HMG-domain protein alters the responses of cells to cisplatin. , 2002, Journal of inorganic biochemistry.

[4]  A. Marrone,et al.  Insight into the Substitution Mechanism of Antitumor Au(I) N-Heterocyclic Carbene Complexes by Cysteine and Selenocysteine. , 2020, Inorganic chemistry.

[5]  N. Brown,et al.  Cloning and Functional Analysis of thepbr Lead Resistance Determinant of Ralstonia metallidurans CH34 , 2001, Journal of bacteriology.

[6]  J. Coward,et al.  Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. , 2016, Critical reviews in oncology/hematology.

[7]  BARNETT ROSENBERG,et al.  Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.

[8]  T. Roane.  Lead Resistance in Two Bacterial Isolates from Heavy Metal–Contaminated Soils , 1999, Microbial Ecology.

[9]  A. Marrone,et al.  Activation and Reactivity of a Bispidine Analogue of Cisplatin: A Theoretical Investigation. , 2016, The journal of physical chemistry. A.

[10]  S. Berners‐Price,et al.  Gold compounds as therapeutic agents for human diseases. , 2011, Metallomics : integrated biometal science.

[11]  Askar Yimit,et al.  Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs , 2019, Nature Communications.

[12]  F. C. Soncini,et al.  Bacterial gold sensing and resistance , 2011, BioMetals.

[13]  A. Marrone,et al.  Insight into the Electrochemical Reduction Mechanism of Pt(IV) Anticancer Complexes. , 2018, Inorganic chemistry.

[14]  D. Gündisch,et al.  Bispidine as a Privileged Scaffold. , 2016, Current topics in medicinal chemistry.

[15]  M. Ginanneschi,et al.  Insights on the mechanism of thioredoxin reductase inhibition by gold N-heterocyclic carbene compounds using the synthetic linear selenocysteine containing C-terminal peptide hTrxR(488-499): an ESI-MS investigation. , 2014, Journal of inorganic biochemistry.

[16]  A Multi-Level Theoretical Study to Disclose the Binding Mechanisms of Gold(III)-Bipyridyl Compounds as Selective Aquaglyceroporin Inhibitors. , 2017, Chemistry.

[17]  Sara A. Aldossary,et al.  Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin , 2019, Biomedical and Pharmacology Journal.

[18]  A. Hamacher,et al.  Bispidine analogues of cisplatin, carboplatin, and oxaliplatin. synthesis, structures, and cytotoxicity. , 2014, Inorganic chemistry.

[19]  J. Gan,et al.  Structural Basis for the Selective Pb(II) Recognition of Metalloregulatory Protein PbrR691. , 2016, Inorganic chemistry.

[20]  J. Goodisman,et al.  Understanding how the platinum anticancer drug carboplatin works: From the bottle to the cell , 2012 .

[21]  J. Zhao,et al.  Structural Insights and the Surprisingly Low Mechanical Stability of the Au-S Bond in the Gold-Specific Protein GolB. , 2015, Journal of the American Chemical Society.

[22]  Chris Orvig,et al.  Metallodrugs in medicinal inorganic chemistry. , 2014, Chemical reviews.

[23]  T. Boulikas,et al.  Cisplatin and platinum drugs at the molecular level. (Review). , 2003, Oncology reports.

[24]  A. Marrone,et al.  Activation of carboplatin by chloride ions: a theoretical investigation , 2011 .

[25]  R. Gust,et al.  Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. , 2013, Chemical Society reviews.

[26]  Massimiliano Bartolomei,et al.  Noncovalent interactions between cisplatin and graphene prototypes , 2018, J. Comput. Chem..

[27]  A. Marrone,et al.  Insights on the activity of platinum-based anticancer complexes through computational methods , 2018 .

[28]  A. Casini,et al.  Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study , 2009, JBIC Journal of Biological Inorganic Chemistry.

[29]  A. Marrone,et al.  Binding of antitumor ruthenium complexes to DNA and proteins: a theoretical approach. , 2007, Journal of Physical Chemistry B.

[30]  A. Ciavardini,et al.  Vibrational Signatures of the Naked Aqua Complexes from Platinum(II) Anticancer Drugs , 2013 .

[31]  M. Crestoni,et al.  Cisplatin Primary Complex with l-Histidine Target Revealed by IR Multiple Photon Dissociation (IRMPD) Spectroscopy. , 2017, Chemphyschem : a European journal of chemical physics and physical chemistry.

[32]  A. Carnero,et al.  The second generation of iodido complexes: trans-[PtI2(amine)(amine')] bearing different aliphatic amines. , 2013, Journal of inorganic biochemistry.

[33]  A. Marrone,et al.  Reactivity of Gold(I) Monocarbene Complexes with Protein Targets: A Theoretical Study , 2019, International journal of molecular sciences.

[34]  A. Marrone,et al.  Molecular dynamics simulation of the Pb(II) coordination in biological media via cationic dummy atom models , 2021, Theoretical Chemistry Accounts.

[35]  A. Merlino,et al.  Peculiar features in the crystal structure of the adduct formed between cis-PtI2(NH3)2 and hen egg white lysozyme. , 2013, Inorganic chemistry.

[36]  S. Lippard,et al.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.

[37]  Vindi M. Jayasinghe-Arachchige,et al.  Heteromeric three-stranded coiled coils designed using a Pb(ii)(Cys)3 template mediated strategy , 2020, Nature Chemistry.

[38]  S. Berners‐Price,et al.  Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. , 2008, Journal of the American Chemical Society.

[39]  I. Kostova.  Ruthenium complexes as anticancer agents. , 2006, Current medicinal chemistry.

[40]  L. Messori,et al.  Reactions of cisplatin and cis-[PtI2(NH3)2] with molecular models of relevant protein sidechains: A comparative analysis. , 2020, Journal of inorganic biochemistry.

[41]  M. Giampà,et al.  Hydrolysis of cis- and transplatin: structure and reactivity of the aqua complexes in a solvent free environment , 2017 .

[42]  L. Storchi,et al.  Computational investigations of bioinorganic complexes: The case of calcium, gold and platinum ions , 2019, PROCEEDINGS OF THE INTERNATIONAL CONFERENCE OF COMPUTATIONAL METHODS IN SCIENCES AND ENGINEERING 2019 (ICCMSE-2019).

[43]  F. C. Soncini,et al.  Bacterial sensing of and resistance to gold salts , 2007, Molecular microbiology.

[44]  A. Verkman,et al.  Prevention of Skin Tumorigenesis and Impairment of Epidermal Cell Proliferation by Targeted Aquaporin-3 Gene Disruption , 2007, Molecular and Cellular Biology.

[45]  R. Zubarev,et al.  Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug. , 2019, Biochimie.

[46]  A. Marrone,et al.  Activation of carboplatin by carbonate: a theoretical investigation. , 2012, Dalton transactions.

[47]  N. Bešker,et al.  Aquation of the ruthenium-based anticancer drug NAMI-A: a density functional study. , 2008, The journal of physical chemistry. B.

[48]  E. Wexselblatt,et al.  What do we know about the reduction of Pt(IV) pro-drugs? , 2012, Journal of inorganic biochemistry.

[49]  A. Ciavardini,et al.  Cisplatin and transplatin interaction with methionine: bonding motifs assayed by vibrational spectroscopy in the isolated ionic complexes. , 2017, Physical chemistry chemical physics : PCCP.

[50]  O. Crociani,et al.  Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer. , 2019, ACS medicinal chemistry letters.

[51]  Sumit Ghosh.  Cisplatin: The first metal based anticancer drug. , 2019, Bioorganic chemistry.

[52]  Ma del Refugio Cuevas-Flores,et al.  Interaction and Reactivity of Cisplatin Physisorbed on Graphene Oxide Nano-Prototypes , 2020, Nanomaterials.

[53]  P. Dyson,et al.  Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy , 2006 .

[54]  A. Klegeris,et al.  The biological activity of auranofin: implications for novel treatment of diseases , 2012, Inflammopharmacology.

[55]  D. La Mendola,et al.  Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PEt3)I: A Theoretical and Experimental Study , 2020, Frontiers in Chemistry.

[56]  B. Lippert.  Impact of Cisplatin on the Recent Development of Pt Coordination Chemistry: A Case Study , 1999 .

[57]  F. Da Settimo,et al.  A mixed-valence diruthenium(II,III) complex endowed with high stability: from experimental evidence to theoretical interpretation. , 2020, Dalton transactions.